IBA Molecular, a global leader in the manufacture and distribution of radiopharmaceuticals, announced today the completion of the previously announced sale of its US operations, IBA Molecular North America, Inc. (IBAM NA), to Illinois Health and Science (IHS), a non-profit healthcare system based in Decatur, Illinois. The divestiture includes all of IBAM NA's cyclotron sites and its research and development facilities. Terms of the transaction were not disclosed. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A.
Commenting on the closing, Renaud Dehareng, CEO of IBA Molecular, said "We are excited to announce the closing of the sale of IBAM NA to IHS. I would like to personally thank all of IBAM NA's employees for their commitment, dedication and hard work. The future for IBAM NA is bright under IHS' ownership given their leadership in nuclear medicine and strong commitment to customers, employees and patients."
Rothschild Inc. served as exclusive financial advisor to IBA Molecular for the transaction.
New study aims to reduce bias in AI health prediction models